重组人血管内皮抑制素对中晚期非小细胞肺癌肿瘤因子的影响  

The Effect of Recombinant Human Endostatin on Tumor Factors in Middle and Advanced Stage Non-small Cell Lung Cancer

作　　者：朱绪臻 ZHU Xuzhen(Department of OncologyⅢ,Yankuang New Mileage General Hospital,Zoucheng 273500,China)

机构地区：[1]兖矿新里程总医院肿瘤三科,山东邹城273500

出　　处：《中国医学创新》2024年第4期58-62,共5页Medical Innovation of China

摘　　要：目的:探讨中晚期非小细胞肺癌(NSCLC)利用重组人血管内皮抑制素方案对治疗效果的影响。方法:选取2020年4月—2023年1月兖矿新里程总医院肿瘤三科收治的中晚期NSCLC患者98例,以随机法分组,分成观察组及对照组,各49例。对照组应用常规化疗方案,持续3个疗程,观察组在对照组基础上加用重组人血管内皮抑制素,持续3个疗程。对比两组治疗效果,对比两组治疗前与治疗3个疗程血清细胞角蛋白19片段(Cyfra21-1)、血管内皮生长因子(VEGF)水平、癌胚抗原(CEA)指标水平,对比两组治疗前与治疗3个疗程的生活质量(SF-36)评分,观察并对比两组不良反应发生率。结果:观察组总有效率高于对照组(P<0.05);治疗3个疗程,两组血清CEA、Cyfra21-1、VEGF均下降,而观察组均比对照组低,差异均有统计学意义(P<0.05);治疗3个疗程,两组生活质量评分均高于治疗前,观察组均高于对照组,差异均有统计学意义(P<0.05);疗程期间两组不良反应差异均无统计学意义(P>0.05)。结论:重组人血管内皮抑制素协助传统化疗制剂用于中晚期NSCLC的治疗,有助于下调血清CEA、Cyfra21-1、VEGF水平,提升生活质量的同时也不会加重不良反应。Objective:To investigate the impact of using recombinant human endostatin on the treatment efficacy of middle and advanced stage non-small cell lung cancer(NSCLC).Method:A total of 98 patients with middle and advanced stage NSCLC admitted to the Department of OncologyⅢ,Yankuang New Mileage General Hospital from April 2020 to January 2023 were selected and randomly divided into the observation group and the control group,with 49 patients in each group.The control group received conventional chemotherapy for 3 cycles,while the observation group received additional Recombinant Human Endostatin therapy on the basis of the control group for 3 cycles.The treatment efficacy,serum levels of cytokeratin 19 fragment(Cyfra21-1),vascular endothelial growth factor(VEGF),and carcinoembryonic antigen(CEA)before treatment and after 3 cycles of treatment,as well as the quality of life(SF-36)scores before treatment and after 3 cycles of treatment were compared between the two groups.The incidence of adverse reactions was also observed and compared.Result:The total effective rate in the observation group was higher than that in the control group(P<0.05).After 3 cycles of treatment,the serum levels of CEA,Cyfra21-1,and VEGF in both groups decreased,with lower levels in the observation group compared to the control group,the differences were statistically significant(P<0.05).After 3 cycles of treatment,the quality of life scores in both groups increased compared to before treatment,with higher scores in the observation group compared to the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period(P>0.05).Conclusion:The use of Recombinant Human Endostatin as an adjuvant to conventional chemotherapy in the treatment of middle and advanced stage NSCLC helps reduce serum levels of CEA,Cyfra21-1,and VEGF while improving the quality of life without aggravating adverse reactions.

关 键 词：非小细胞肺癌 中晚期 重组人血管内皮抑制素 癌胚抗原 细胞角蛋白19片段 血管 内皮生长因子 

分 类 号：R734.2[医药卫生—肿瘤]